Male Fertility Debate: Sperm Decline Claims Split Scientists
SkimNews Take
The genuine crisis may be methodological: competing sperm-count datasets and shifting reference populations let scientists reach opposite conclusions, meaning public health guidance on male fertility will keep lagging behind whichever headline prevails.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Prof Hagai Levine presented data suggesting average male testosterone levels have halved over the past 50 years, calling it a 'mind-blowing' public health emergency
- Levine and Prof Shanna Swan have promoted a 'spermageddon' narrative, with Swan projecting sperm counts could reach zero by 2045, sparking alarm across media and political spheres
- Prof Allan Pacey disputes the sperm count decline, citing more consistent measurement methods that show no substantial drop, though he acknowledges worsening sperm quality
- Prof Channa Jayasena attributes falling testosterone levels primarily to rising obesity and diabetes, noting each one-point BMI increase may reduce testosterone by 2%
- Prof Rod Mitchell conducted controlled experiments with human fetal testes tissue and found no effect on testosterone or testicular development from plasticizers like phthalates and BPA
- Prof Christopher Barratt criticizes the stagnation in sperm analysis since the 1950s and warns against unproven fertility 'add-ons' and the misuse of testosterone replacement therapy, which can suppress sperm production
- Silicon Valley startups, including Paterna, are advancing lab-grown sperm from stem cells, with one claiming to have created healthy-looking embryos, signaling potential future options for male infertility
Why it matters: Men may face worsening fertility outcomes if lifestyle trends and environmental exposures continue unchecked, while premature adoption of unproven treatments risks exacerbating the problem; the stakes are high because current clinical tools remain outdated and regulatory oversight lags behind commercial fertility innovations.
